DLA Piper has advised Orchidia Pharmaceutical Industries (the "Company" or "Orchidia"), a leading ophthalmic generic medicine manufacturer and one of Egypt's fastest growing pharmaceutical companies, and Dr. Ossama Fouad Abbas, the founder, majority shareholder and Chairman of the Company, on the sale of a stake in the Company and two holding companies incorporated in Cyprus to Egyptian-American Enterprise Fund (EAEF).

DLA Piper advised on all aspects of the transaction which involved the swapping of Dr. Ossama's and certain minority shareholders' shares in the Company to a holding company in Cyprus and a capital increase in another holding company in Cyprus which Dr. Ossama, EAEF and certain minority shareholders will subscribe to.

The proceeds of the capital increase will be used to support the Company's future growth plans to cater to the growing Egyptian market and develop Egypt's export potential.

The Dubai-based DLA Piper team was led by Corporate legal director, Thérèse Abou-Zeid, who was assisted by Corporate associate, Philippe Habib.

Thérèse Abou-Zeid, said: "We are delighted to have worked with Dr. Ossama Abbas and the Orchidia team to position the Company for its next phase of growth. The transaction builds upon DLA Piper's extensive regional and global experience advising pharmaceutical companies at various stages of their investment life cycle, from start-ups and fast-growing mid-market businesses to mature global enterprises."